Glycemic pharmacotherapy comprises agents acting on opposite directions of glucose regulation: insulin sensitizers reduce peripheral insulin resistance and hepatic glucose production, alpha-glucosidase inhibitors limit intestinal carbohydrate absorption, and glycogenolytic agents mobilize hepatic glycogen stores to raise blood glucose in severe hypoglycemia. Each agent's site of action determines its contraindication set — a sensitizer causing fluid retention is barred by cardiac failure, and a gut-acting absorption inhibitor is barred by gastrointestinal disease — illustrating the general principle that where a drug acts defines which comorbidity excludes it. The topic belongs to endocrine pharmacology within nursing pharmacotherapeutics and connects glucose homeostasis physiology to the bidirectional correction of both hyperglycemia and hypoglycemia.
Glycemic pharmacotherapy comprises agents acting on opposite directions of glucose regulation: insulin sensitizers reduce peripheral insulin resistance and hepatic glucose production, alpha-glucosida…